Laura De Giglio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1925501/publications.pdf Version: 2024-02-01



LALIDA DE CICLIO

#	Article	IF	CITATIONS
1	Pregnancy and fetal outcomes after interferon-Î ² exposure in multiple sclerosis. Neurology, 2010, 75, 1794-1802.	1.1	142
2	Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology, 2011, 77, 145-150.	1.1	135
3	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.1	102
4	Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 64-71.	3.0	85
5	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	1.8	82
6	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	1.8	78
7	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.1	74
8	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	1.9	66
9	Oral contraceptives combined with interferon \hat{I}^2 in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e120.	6.0	64
10	A Low-Cost Cognitive Rehabilitation With a Commercial Video Game Improves Sustained Attention and Executive Functions in Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 453-461.	2.9	60
11	Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Multiple Sclerosis Journal, 2007, 13, 1086-1094.	3.0	50
12	Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program. Radiology, 2016, 280, 202-211.	7.3	48
13	Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 566-576.	3.0	45
14	Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurologica Scandinavica, 2015, 131, 336-340.	2.1	43
15	Neuroimaging Techniques to Assess Inflammation in Multiple Sclerosis. Neuroscience, 2019, 403, 4-16.	2.3	40
16	Investigating the phenomenon of "cognitive-motor interference―in multiple sclerosis by means of dual-task posturography. Gait and Posture, 2015, 41, 780-785.	1.4	38
17	Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. CNS Drugs, 2018, 32, 963-970.	5.9	35
18	Fingolimod vs dimethyl fumarate in multiple sclerosis. Neurology, 2018, 91, e153-e161.	1.1	35

LAURA DE GIGLIO

#	Article	IF	CITATIONS
19	Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features. Multiple Sclerosis Journal, 2017, 23, 546-555.	3.0	34
20	Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Neurotherapeutics, 2020, 17, 994-1004.	4.4	34
21	Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurological Sciences, 2005, 26, s174-s178.	1.9	31
22	Task-dependent deterioration of balance underpinning cognitive-postural interference in MS. Neurology, 2016, 87, 1085-1092.	1.1	31
23	Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 271-277.	1.9	29
24	The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis. Headache, 2012, 52, 1130-1135.	3.9	28
25	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	1.8	27
26	Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis. Radiology, 2018, 287, 267-275.	7.3	25
27	Estimating the impact of COVID-19 pandemic on services provided by Italian Neuromuscular Centers: an Italian Association of Myology survey of the acute phase. Acta Myologica, 2020, 39, 57-66.	1.5	24
28	Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial. CNS Drugs, 2017, 31, 161-168.	5.9	23
29	Mood and coping in clinically isolated syndrome and multiple sclerosis. Acta Neurologica Scandinavica, 2014, 129, 374-381.	2.1	22
30	Lesion symptom map of cognitive–postural interference in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 653-662.	3.0	21
31	Relation between functional connectivity and disability in multiple sclerosis: a non-linear model. Journal of Neurology, 2018, 265, 2881-2892.	3.6	21
32	Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology, 2019, 93, e733-e746.	1.1	21
33	Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?. BMC Neurology, 2011, 11, 26.	1.8	19
34	A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta. Multiple Sclerosis and Related Disorders, 2016, 8, 99-106.	2.0	19
35	Premorbid functional reserve modulates the effect of rehabilitation in multiple sclerosis. Neurological Sciences, 2020, 41, 1251-1257.	1.9	18
36	Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis. Journal of Neurology, 2021, 268, 4834-4845.	3.6	16

LAURA DE GIGLIO

#	Article	IF	CITATIONS
37	Determinants of the severity of comorbid migraine in multiple sclerosis. Neurological Sciences, 2012, 33, 1345-1353.	1.9	15
38	Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis. Mediators of Inflammation, 2015, 2015, 1-5.	3.0	15
39	Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis. Journal of the Neurological Sciences, 2016, 370, 211-213.	0.6	13
40	Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 153.	2.4	13
41	Multi-scale resting state functional reorganization in response to multiple sclerosis damage. Neuroradiology, 2020, 62, 693-704.	2.2	13
42	Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. Multiple Sclerosis Journal, 2021, 27, 1939-1947.	3.0	13
43	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	3.0	13
44	Cognitive fatigability is a quantifiable distinct phenomenon in multiple sclerosis. Journal of Neuropsychology, 2020, 14, 370-383.	1.4	11
45	A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 529.	2.4	11
46	A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis. Journal of Neurology, 2021, 268, 4698-4706.	3.6	11
47	<i>Listeria monocytogenes</i> –Induced Rhombencephalitis in a Patient With Multiple Sclerosis Treated With Dimethyl Fumarate. JAMA Neurology, 2018, 75, 762.	9.0	10
48	Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. Multiple Sclerosis and Related Disorders, 2019, 27, 239-246.	2.0	9
49	ATTRv in Lazio-Italy: A High-Prevalence Region in a Non-Endemic Country. Genes, 2021, 12, 829.	2.4	9
50	Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19. Neurological Sciences, 2020, 42, 2903-2910.	1.9	8
51	The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray). PLoS ONE, 2019, 14, e0219670.	2.5	7
52	Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial. Neurotherapeutics, 2020, 17, 704-709.	4.4	5
53	Aminopiridines in the treatment of multiple sclerosis and other neurological disorders. Neurodegenerative Disease Management, 2020, 10, 409-423.	2.2	5
54	Cesarean section in women with MS: A choice or a need?. Multiple Sclerosis and Related Disorders, 2020, 38, 101867.	2.0	3

LAURA DE GIGLIO

#	Article	IF	CITATIONS
55	Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients. Frontiers in Neurology, 2021, 12, 632917.	2.4	3
56	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	3.0	3
57	Treatment of multiple sclerosis-related fatigue: pharmacological and non-pharmacological approaches. Neurological Sciences, 2006, 27, s297-s299.	1.9	2
58	Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 417-429.	2.8	2
59	Post-COVID simultaneous onset of Graves' disease and ocular myasthenia gravis in a patient with a complex ocular motility impairment. European Journal of Ophthalmology, 2023, 33, NP49-NP51.	1.3	2
60	Atypical motor neuron disease with bent spine clinical onset and long survival carrying C9orf72 expansion. Neurological Sciences, 2021, 42, 353-355.	1.9	1
61	<i>Listeria Monocytogenes</i> –Induced Rhombencephalitis—A Paradoxical Disease of Immunocompetent Patients—Reply. JAMA Neurology, 2018, 75, 1442.	9.0	0
62	â€~Posture second' strategy predicts disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1140-1144.	3.0	0
63	Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110112.	3.5	0